Amy Elazzouzi Sells 8,549 Shares of Aura Biosciences (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 8,549 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total transaction of $43,257.94. Following the completion of the sale, the senior vice president directly owned 75,532 shares in the company, valued at approximately $382,191.92. The trade was a 10.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 20th, Amy Elazzouzi sold 1,581 shares of Aura Biosciences stock. The shares were sold at an average price of $4.86, for a total transaction of $7,683.66.

Aura Biosciences Trading Down 4.0%

Aura Biosciences stock opened at $5.04 on Thursday. The company has a market cap of $320.04 million, a PE ratio of -2.60 and a beta of 0.46. Aura Biosciences, Inc. has a 1 year low of $4.34 and a 1 year high of $7.80. The company’s 50-day moving average is $5.57 and its two-hundred day moving average is $5.96.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its position in Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $40,000 after buying an additional 2,104 shares during the last quarter. Water Island Capital LLC bought a new position in shares of Aura Biosciences during the 3rd quarter worth approximately $64,000. 49 Wealth Management LLC bought a new position in shares of Aura Biosciences during the 3rd quarter worth approximately $66,000. ProShare Advisors LLC acquired a new position in shares of Aura Biosciences during the 4th quarter worth approximately $59,000. Finally, Invesco Ltd. bought a new stake in Aura Biosciences in the 2nd quarter valued at $76,000. Institutional investors own 96.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, December 29th. Evercore started coverage on shares of Aura Biosciences in a research report on Tuesday, November 25th. They issued an “outperform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Key Stories Impacting Aura Biosciences

Here are the key news stories impacting Aura Biosciences this week:

• Neutral Sentiment: Short-interest report flagged a “large increase” for Feb. 16–17 but shows 0 shares and NaN changes, indicating a likely data/reporting error rather than new short activity. Treat this as informational but not a confirmed market driver. Short interest article
• Negative Sentiment: Cluster of insider sales — Company insiders sold ~104,567 shares combined (approx. $525k–$530k proceeds), reducing individual holdings by ~6–10% each. Notable filings: Los Pinos Elisabet De sold 47,648 shares (~$5.06 avg), Amy Elazzouzi (SVP) sold 8,549 shares (~$5.06), Janet Jill Hopkins sold 20,401 shares (~$5.06), CTO Mark Plavsic sold 15,890 shares (~$5.05), and Conor Kilroy sold 12,079 shares (~$5.05). Large, concurrent insider selling often creates near-term selling pressure and investor concern. SEC filings: Los Pinos filing Elazzouzi filing Hopkins filing Plavsic filing Kilroy filing

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.